JP2016515137A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016515137A5 JP2016515137A5 JP2016502527A JP2016502527A JP2016515137A5 JP 2016515137 A5 JP2016515137 A5 JP 2016515137A5 JP 2016502527 A JP2016502527 A JP 2016502527A JP 2016502527 A JP2016502527 A JP 2016502527A JP 2016515137 A5 JP2016515137 A5 JP 2016515137A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- treatment cycle
- apoe mimetic
- apoe
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000013918 Apolipoproteins E Human genes 0.000 claims description 38
- 108010025628 Apolipoproteins E Proteins 0.000 claims description 38
- 238000011282 treatment Methods 0.000 claims description 28
- 230000001225 therapeutic effect Effects 0.000 claims description 8
- 201000001320 Atherosclerosis Diseases 0.000 claims description 7
- 230000016507 interphase Effects 0.000 claims description 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 230000003278 mimic effect Effects 0.000 claims description 6
- 229940124597 therapeutic agent Drugs 0.000 claims description 6
- 150000002632 lipids Chemical class 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 4
- 230000002459 sustained effect Effects 0.000 claims description 3
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 2
- 125000003368 amide group Chemical group 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- 230000003143 atherosclerotic effect Effects 0.000 claims 1
- 230000003797 telogen phase Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 11
- 238000002648 combination therapy Methods 0.000 description 2
- 238000011221 initial treatment Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361782956P | 2013-03-14 | 2013-03-14 | |
| US61/782,956 | 2013-03-14 | ||
| US201361834992P | 2013-06-14 | 2013-06-14 | |
| US61/834,992 | 2013-06-14 | ||
| PCT/US2014/027719 WO2014152776A1 (en) | 2013-03-14 | 2014-03-14 | Apolipoprotein mimetics and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019026743A Division JP6772317B2 (ja) | 2013-03-14 | 2019-02-18 | アポリポタンパク質模倣体及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016515137A JP2016515137A (ja) | 2016-05-26 |
| JP2016515137A5 true JP2016515137A5 (enExample) | 2017-04-20 |
| JP6570511B2 JP6570511B2 (ja) | 2019-09-04 |
Family
ID=51581312
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016502527A Expired - Fee Related JP6570511B2 (ja) | 2013-03-14 | 2014-03-14 | アポリポタンパク質模倣体及びその使用 |
| JP2019026743A Expired - Fee Related JP6772317B2 (ja) | 2013-03-14 | 2019-02-18 | アポリポタンパク質模倣体及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019026743A Expired - Fee Related JP6772317B2 (ja) | 2013-03-14 | 2019-02-18 | アポリポタンパク質模倣体及びその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20160002315A1 (enExample) |
| EP (1) | EP2996706B1 (enExample) |
| JP (2) | JP6570511B2 (enExample) |
| AU (2) | AU2014239186B2 (enExample) |
| BR (1) | BR112015022624A2 (enExample) |
| CA (1) | CA2903869A1 (enExample) |
| DK (1) | DK2996706T3 (enExample) |
| ES (1) | ES2753381T3 (enExample) |
| IL (1) | IL240787B (enExample) |
| MX (1) | MX2015012818A (enExample) |
| NZ (1) | NZ713291A (enExample) |
| WO (1) | WO2014152776A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2954475C (en) | 2014-07-31 | 2023-05-16 | Uab Research Foundation | Apoe mimetic peptides and higher potency to clear plasma cholesterol |
| WO2017120568A1 (en) * | 2016-01-08 | 2017-07-13 | Lipimetix Development, Inc. | Apoe mimetic peptide compositions |
| MA44234B1 (fr) * | 2016-02-17 | 2023-10-31 | Regeneron Pharma | Procédés de traitement ou de prévention de l'athérosclérose par administration d'un inhibiteur d'angptl3 |
| EA201891979A1 (ru) | 2016-03-03 | 2019-01-31 | Ридженерон Фармасьютикалз, Инк. | Способы лечения пациентов с гиперлипидемией введением ингибитора pcsk9 в комбинации с ингибитором angptl3 |
| WO2023018876A2 (en) * | 2021-08-11 | 2023-02-16 | The Regents Of The University Of California | Barrier function preserving peptides for membranes |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO812612L (no) | 1980-08-06 | 1982-02-08 | Ferring Pharma Ltd | Enzym-inhibitorer. |
| GB9022788D0 (en) | 1990-10-19 | 1990-12-05 | Cortecs Ltd | Pharmaceutical formulations |
| US5331573A (en) | 1990-12-14 | 1994-07-19 | Balaji Vitukudi N | Method of design of compounds that mimic conformational features of selected peptides |
| US5631280A (en) | 1995-03-29 | 1997-05-20 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US6506880B2 (en) | 1998-03-17 | 2003-01-14 | The Uab Research Foundation | Synthetic peptides that enhance atherogenic lipoprotein uptake and lower plasma cholesterol |
| US6664230B1 (en) | 2000-08-24 | 2003-12-16 | The Regents Of The University Of California | Orally administered peptides to ameliorate atherosclerosis |
| US7199102B2 (en) | 2000-08-24 | 2007-04-03 | The Regents Of The University Of California | Orally administered peptides synergize statin activity |
| CA2697957A1 (en) * | 2007-08-28 | 2009-03-12 | Uab Research Foundation | Synthetic apolipoprotein e mimicking polypeptides and methods of use |
| CN102917727B (zh) * | 2010-01-06 | 2017-10-17 | 康石医药科技（上海）有限公司 | Apoe肽及其用途 |
| CA2954475C (en) * | 2014-07-31 | 2023-05-16 | Uab Research Foundation | Apoe mimetic peptides and higher potency to clear plasma cholesterol |
-
2014
- 2014-03-14 WO PCT/US2014/027719 patent/WO2014152776A1/en not_active Ceased
- 2014-03-14 MX MX2015012818A patent/MX2015012818A/es active IP Right Grant
- 2014-03-14 US US14/770,270 patent/US20160002315A1/en not_active Abandoned
- 2014-03-14 CA CA2903869A patent/CA2903869A1/en not_active Abandoned
- 2014-03-14 ES ES14769489T patent/ES2753381T3/es active Active
- 2014-03-14 DK DK14769489.7T patent/DK2996706T3/da active
- 2014-03-14 NZ NZ713291A patent/NZ713291A/en not_active IP Right Cessation
- 2014-03-14 JP JP2016502527A patent/JP6570511B2/ja not_active Expired - Fee Related
- 2014-03-14 BR BR112015022624A patent/BR112015022624A2/pt not_active Application Discontinuation
- 2014-03-14 AU AU2014239186A patent/AU2014239186B2/en not_active Ceased
- 2014-03-14 EP EP14769489.7A patent/EP2996706B1/en active Active
-
2015
- 2015-08-24 IL IL240787A patent/IL240787B/en active IP Right Grant
-
2017
- 2017-06-09 AU AU2017203911A patent/AU2017203911B2/en not_active Ceased
-
2019
- 2019-02-18 JP JP2019026743A patent/JP6772317B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201491285A1 (ru) | Улучшенные композиции и способы доставки омепразола и ацетилсалициловой кислоты | |
| JP2015517488A5 (enExample) | ||
| SG10201407013QA (en) | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases | |
| JP2013520405A5 (enExample) | ||
| JP2015504871A5 (enExample) | ||
| JP2016515137A5 (enExample) | ||
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| CA2923685A1 (en) | Application of r-ketamine and salt thereof as pharmaceuticals | |
| JP2014506583A5 (enExample) | ||
| JP2012502047A5 (enExample) | ||
| RU2015127794A (ru) | Введение антисмысловых олигонуклеотидов, комплементарных человеческому аполипопротеину в | |
| JP2015519329A5 (enExample) | ||
| EA201590166A8 (ru) | Комбинированная терапия для лечения рассеянного склероза | |
| JP2017531033A5 (enExample) | ||
| UA107578C2 (uk) | Комбінована терапія при лікуванні діабету | |
| EA201490377A1 (ru) | Лечение рассеянного склероза комбинацией лаквинимода и глатирамера ацетата | |
| JP2015518818A5 (enExample) | ||
| JP2015517489A5 (enExample) | ||
| JP2019089834A5 (enExample) | ||
| IN2015DN04175A (enExample) | ||
| JP2017530130A5 (enExample) | ||
| RU2010142456A (ru) | Синергические комбинации 5'-метилтиоаденозина | |
| JP2018505882A5 (enExample) | ||
| JP2018530578A5 (enExample) | ||
| JP2017503014A5 (enExample) |